id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-E-2595-0006,FDA,FDA-2018-E-2595,Patent Term Extension Letter from FDA CDER to U S Patent Trademark Office,Other,Letter(s),2020-07-27T04:00:00Z,2020,7,2020-07-28T04:00:00Z,,2020-07-28T16:19:37Z,,0,0,09000064847aceef
FDA-2018-E-2595-0005,FDA,FDA-2018-E-2595,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2020-06-22T04:00:00Z,2020,6,2020-06-22T04:00:00Z,,2020-06-22T17:46:30Z,,0,0,09000064846fef75
FDA-2018-E-2595-0004,FDA,FDA-2018-E-2595,Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC,Notice,Determinations,2019-11-29T05:00:00Z,2019,11,2019-11-29T05:00:00Z,2020-05-28T03:59:59Z,2019-11-29T19:13:51Z,2019-25850,0,0,09000064841c881f
FDA-2018-E-2595-0003,FDA,FDA-2018-E-2595,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,,2019-11-01T20:31:25Z,,0,0,0900006484116879
FDA-2018-E-2595-0002,FDA,FDA-2018-E-2595,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-09-18T04:00:00Z,2018,9,2018-09-18T04:00:00Z,,2018-09-18T18:19:19Z,,0,0,0900006483716253
FDA-2018-E-2595-0001,FDA,FDA-2018-E-2595,Letter from U S Patent and Trademark Office,Other,Letter(s),2018-07-05T04:00:00Z,2018,7,2018-07-05T04:00:00Z,,2018-07-05T18:48:51Z,,0,0,09000064834af68e